Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...
Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback